-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
-
IASLC 18th World Conference on Lung Cancer
Posted: October 2017 At the upcoming IASLC WCLC 2017 Conference, Co-Presidents Hisao Asamura, MD, and Keunchil Park, MD, PhD, will welcome delegates from more than 100 countries who will gather to witness and discuss the latest developments in thoracic malignancy research. The WCLC 2017 motto “Synergy to Conquer Lung Cancer” captures the collaborative spirit of…
-
ADJUVANT Trial of Gefitinib Versus Chemotherapy in Resected EGFR-Mutations Non-Small Cell Lung Cancer
By Heather Wakelee, MD Posted: October 2017 For most of the world, four cycles of cisplatin-based adjuvant chemotherapy is the standard of care for patients with resected stage II and IIIA non-small cell lung cancer (NSCLC), and is offered to many patients with stage IB tumors at least 4 cm in size or larger. This…
-
IASLC Leader Elected President of ESMO for 2020–2021: Solange Peters, MD, PhD
Posted: October 2017 The European Society for Medical Oncology (ESMO) has elected an emerging leader in thoracic oncology—and an IASLC board member—to lead the organization in 2020–2021. ESMO President- Elect Solange Peters, MD, PhD, is head of the medical oncology service and chair of thoracic oncology in the Oncology Department at the Centre Hospitalier Universitaire…
-
PJ Souquet, MD
Posted: October 2017 PJ Souquet, MD was appointed President of The French Cooperative Thoracic Intergroup (Intergroupe Francophone de Cancèrologie Thoracique IFCT). Dr. Souquet, is Head of Service at the Hospices Civils de Lyon, Lyon, and Associate Professor of Medecine, at South-Lyon University, France.
-
Ellen V. Sigal, PhD: Leading the Cancer Research Advocacy Community
By Lori Alexander, MTPW, ELS, MWC® Ellen Sigal’s unsurpassed passion for cancer research advocacy was ignited 30 years ago after the devastating loss of her younger sister Gale to breast cancer. Her drive to make a difference led her to establish Friends of Cancer Research (Friends), a nonprofit advocacy organization based in Washington, DC. Since…
-
Breaking News Briefs
• Dabrafenib and trametidnib (Tafinlar and Mekinist) received FDA approval for use in combination for patients with metastatic non-small cell lung cancer (NSCLC) with BRAFV600E mutation as detected by an FDAapproved test. This is the first FDA approval specifically for treatment of patients with BRAFV600E mutationpositive metastatic NSCLC. (6/22/17) • The FDA also approved the…
-
NCI Corner – Interview with Jeff Abrams
NCI Helping to Save Lives and Improve Cancer Survival Rates Scientific data from clinical trials are essential for evaluating new cancer treatments and setting new standards of care for patients. The National Cancer Institute (NCI) has supported clinical trials for over 50 years through the Cooperative Group Program, which has produced many important improvements in…
-
Suicide and Lung Cancer: Screening Is Only the First Step
By Kelly Irwin, MD MPH* Assessment of emotional well-being is an essential component of quality cancer care now mandated by the American College of Surgeons; yet oncologists receive limited guidance on when and how to screen and what to do next. Recognizing the elevated suicide risk among patients with cancer is a critical reminder for…
-
Profile of Advocacy: Shanghai Cancer Recovery Club
IASLC Lung Cancer News is pleased to present the following Q&A with the staff of Shanghai Cancer Recovery Club, an organization in Shanghai, China, whose mission is ‘’spreading the idea that cancer does not equal death, carrying forward the work of cancer fighting groups, and ‘transcending life’.’’ Please describe the purpose of the Shanghai Cancer…
-
In Speech to Agency, New FDA Commissioner Highlights Anti-Smoking Efforts
By Erik T. MacLaren, PhD On May 11, 2017, Scott Gottlieb, MD, was sworn in as the 23rd Commissioner of Food and Drugs of the US Food and Drug Administration (FDA). Dr. Gottlieb previously served as Deputy Commissioner for Medical and Scientific Affairs at the FDA, and his background includes experience in medicine, medical policy,…